The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo

Background: The 5-lipoxygenase metabolites of arachidonic acid are likely to be involved in the pathophysiology of atopic asthma. We investigated the effect of pretreatment with MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on allergen-induced early asthmatic reactions (EARs) and lat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 1995, Vol.95 (1), p.42-51
Main Authors: Diamant, Zuzana, Timmers a, Mieke C., van der Veen a, Hilly, Friedman, Beth S., Smet, Marina De, Depré, Marleen, Hilliard, Deborah, Bel, Elisabeth H., Sterk, Peter J.
Format: Article
Language:English
Subjects:
5-Lipoxygenase-Activating Proteins
Administration, Oral
Adult
allergen bronchial provocation tests
Allergens - adverse effects
Allergic diseases
Asthma
Asthma - drug therapy
Asthma - metabolism
Asthma - physiopathology
Biological and medical sciences
bronchial hyperreactivity
Bronchial Hyperreactivity - drug therapy
Bronchial Hyperreactivity - metabolism
Bronchial Hyperreactivity - physiopathology
Bronchial Provocation Tests - methods
Carrier Proteins - antagonists & inhibitors
Creatinine - urine
Double-Blind Method
Forced Expiratory Volume - drug effects
Histamine
Humans
Immunopathology
Indoles - administration & dosage
Indoles - blood
Leukotriene Antagonists
leukotrienes
Leukotrienes - analysis
Leukotrienes - biosynthesis
Male
Medical sciences
Membrane Proteins - antagonists & inhibitors
Quinolines - administration & dosage
Quinolines - blood
Respiratory and ent allergic diseases
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The 5-lipoxygenase metabolites of arachidonic acid are likely to be involved in the pathophysiology of atopic asthma. We investigated the effect of pretreatment with MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on allergen-induced early asthmatic reactions (EARs) and late asthmatic reactions (LARs), and subsequent airway hyperresponsiveness to histamine. Methods: Eight atopic men with mild to moderate asthma aged 19 to 31 years, (forced expiratory volume in 1 second [FEV 1] ≥67% of predicted value, histamine provocative concentration causing a 20% fall in FEV 1 [PC 20]
ISSN:0091-6749
1097-6825
DOI:10.1016/S0091-6749(95)70151-6